DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately six "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

18 Aug 2011

Boost Seminar: Clinical Development for the First Time?

MVA and Pharmacosmos CRO invite you to a seminar on how a small biotech can succeed with their clinical development programs at the MVA auditorium in Ørestaden. The seminar will after a short introduction to clinical development present four cases of successful development programs.

The presenting companies will be Rose Pharma (former Gastrotech Pharma) (in the early phase of development), Zymenex (which sold a clinical program to Shire in 2008), Symphogen (a more mature biotech company with numerous development projects) and Pharmacosmos (a fully integrated Pharmaceutical company with products on the market).

Tentative Programme

09.30-10.00 Registration and Breakfast
10.00-10.15 Introduction
(MVA and Jeppe Skytte, Sales and Business Development, Pharmacosmos CRO A/S)
10.15-10.30 Clinical Development
(Lars Lykke Thomsen, Vice President Chief Medical Office, Pharmacosmos A/S)
10.30-10.45 Case I: What did we do – Rose Pharma (former Gastrotech Pharma)
(Hans Schambye, Chairman Board of Directors)
10.45-11.00 Case II: What did we do – Zymenex
(Pia Ringholm, Director of Regulatory and Quality)
11.00-11.15 Case III: What did we do – Symphogen
(Mimi Folden Flensburg, Director Clinical Development, Symphogen A/S)
11.15-11.30 Case IV: What did we do – Pharmacosmos
(Lars Lykke Thomsen, Vice President Chief Medical Office, Pharmacosmos A/S)
11.30-12.00 Break
12.00-12.10 IP – moving from a “Discovery IP” setting to a “Clinical IP” setting
(Torben Ravn Rasmussen, Awapatent A/S)
12.10-12.25 Regulatory Considerations
(Kim Nordfjeld, Vice President Quality and Regulatory Affairs, Pharmacosmos A/S)
12.25-12.40 Market Access / Pharmaco Economics
(Claes Strøm, Vice President Medical Affairs, Pharmacosmos A/S)
12.40-12.55 Financing Opportunity for early Biotech entrepreneurs: Prospektus
(Sven Poulsen, CEO Okkerhuset ApS)
13.00-13.30 Panel discussion – Please join our speakers in a discussion on challenges and do’s and don’ts
13.30 – Lunch – MVA and Pharmacosmos CRO invites all participant to a light lunch.

Please register on www.mva.org

If you can't find it here or have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2011 Danskbiotek. All rights reserved.